Business Context and Reporting Period
Revvity, Inc. (RVTY) filed a Form 8-K on May 5, 2026, reporting financial results for the first quarter ended April 5, 2026. The company is incorporated in Massachusetts and trades on the New York Stock Exchange.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the full Q1 2026 financial results but does not explicitly state specific values for revenue, profit, cash flow, margins, debt, or liquidity within the text of this 8-K. The filing notes the existence of 1.875% Notes due 2026.
Material Changes and Corporate Events
- Divestiture: On April 16, 2026, Revvity signed a letter of intent to sell all assets related to its Immunodiagnostics business in China ("China IDX").
- Transaction Value: The sale is valued at up to $200 million, subject to adjustments and satisfaction of conditions.
- Pro Forma Data: Unaudited pro forma condensed consolidated financial statements reflecting the probable sale are included as Exhibit 99.2.
Guidance, Outlook, and Risks
Management believes the China IDX transaction is probable and expects it to close in 2027. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks including the company's ability to execute acquisitions and divestitures. No specific financial guidance or outlook figures are provided in this document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, earnings, and cash flow figures not detailed in the 8-K text.
- Examine Exhibit 99.2 for the impact of the China IDX divestiture on pro forma financial position.
- Monitor the status of the $200 million China IDX sale, noting the expected 2027 closing date and potential adjustments to the purchase price.
- Verify the status of the 1.875% Notes due 2026 given the filing date of May 2026.